Searchable abstracts of presentations at key conferences on calcified tissues

ba0003pp170 | Cell biology: osteoclasts and bone resorption | ECTS2014

DBZ, a γ-secretase inhibitor, suppresses bone resorption by inhibiting c-Src activity

Jin Won Jong , Kim Ha-Neui , Kim Hong-Hee , Lee Zang Hee

Tyrosine kinase c-Src plays an important role in actin ring formation and bone resorption activity in osteoclasts. Therefore, c-Src has been targeted for the treatment of osteolytic disorders. In the present study, we investigated anti-resorptive effect of dibenzazepine (DBZ), one of the γ-secretase inhibitors (GSIs), on osteoclast-mediated excessive bone resorption. DBZ did not affect osteoclast differentiation, but disturbed actin ring formation and inhibited osteoclast...

ba0005p223 | Energy metabolism and bone, fat and bone | ECTS2016

Cyclic AMP/protein kinase A signalling downregulates Dlx5 expression via inducing C/Ebpβ in 3T3-L1 preadipocytes

Baek Jeong-Hwa , Lee Hye-Lim , Qadir Abdul , Kim Hyun Jeong , Chung Jin , Woo Kyung Mi , Ryoo Hyun-Mo

Distal-less homeobox 5 (Dlx5) is a transcription factor that enhances osteogenic differentiation of mesenchymal stem cells via upregulating the expression of Runx2 and other osteoblast phenotypic genes. We have previously demonstrated that Dlx5 also downregulates adipogenic differentiation of mesenchymal stem cells and that insulin decreases expression levels of Dlx5 via increasing expression levels of miR-124, a microRNA targeting 3′UTR of Dlx5. However, the mechanism o...

ba0004p193 | (1) | ICCBH2015

Aggravated bone density decline following symptomatic osteonecrosis in children with acute lymphoblastic leukemia

den Hoed MAH , SMF Pluijm , de Groot-Kruseman HA , Fiocco M , Hoogerbrugge P , JA Leeuw , MCA Bruin , van der Sluis IM , Bresters D , MH Lequin , JC Roos , AJP Veerman , Pieters R , van den Heuvel-Eibrink MM

Objectives: Osteonecrosis (ON) and decline of bone mineral density (BMD) are serious side effects during and after treatment of childhood acute lymphoblastic leukemia (ALL). It is unknown whether ON and low BMD co-occur in the same patients, and whether these two osteogenic side-effects can mutually influence each other’s development.Methods: BMD and the incidence of symptomatic ON were prospectively assessed in a national cohort of 466 patients wit...

ba0005cabs.op1.3 | Oral Poster Talks | ECTS2016

Cripto/Grp78 drive the metastatic phenotype in human osteotropic prostate cancer

Zoni Eugenio , Chen Lanpeng , Granchi Zoraide , Karkampouna Sofia , La Manna Federico , Verhoef Ester , Pelger Rob , Snaar-Jagalska Ewa , van Leenders Geert , Beimers Lijkele , Kloen Peter , Gray Peter , van der Pluijm Gabri , Kruithof-de Julio Marianna

Prostate cancer is the most prevalent cancer in men and metastatic spread to bone is detected in up to 80% of patients with advanced disease at autopsy. PCa can progress from treatable androgen-dependent stage to castration-resistant stage with distant metastases for which novel therapeutic targets and strategies are urgently needed. Here we identify the cell surface/secreted oncoprotein Cripto as a potential target for the diagnosis and treatment of metastatic prostate cancer...

ba0001pp129 | Calciotropic and phosphotropic hormones and mineral metabolism | ECTS2013

The Ellsworth-Howard test revisited

Tang J C Y , Washbourne C J , Galitzer H , Hiemstra T , Meek C , Chipchase A , Fraser W D

Background: Pseudohypoparathyroidism (PHP) is a group of heterogeneous endocrine disorders characterised by hormone resistance, primarily to parathyroid hormone (PTH). The resistance is caused by defects in the GNAS gene, which encodes the Gsα protein that activates the cAMP pathway. PHP patients demonstrate elevated plasma PTH, hypocalcaemia, hyperphosphataemia with normal renal function. PTH resistance can be confirmed by Ellsworth-Howard test (PTH s...

ba0002p76 | (1) | ICCBH2013

Final height and bone health in young adults, transplanted in childhood

Dyck Maria Van , Herman Jean , Lombaerts Rita

: This study analyses the long-term effect of rhGH on final height (FH) and bone health in renal transplanted patients.Twenty-one young adult patients, aged 17–26 years, were studied. Group A consisted of 15 patients (12 boys) who received rhGH during 3.0 years before transplantation. After transplantation three boys needed rhGH again for 3.5 years. In group B six patients (three boys) didn’t need rhGH before transplantation, three girls receiv...

ba0003pp192 | Genetics | ECTS2014

Genetic determinants of bone mineral density loss in aromatase inhibitors treatment in the B-ABLE Cohort

Rodriguez-Sanz Maria , Garcia-Giralt Natalia , Torres-del Pliego Elisa , Prieto-Alhambra Daniel , Servitja Sonia , Balcells Susana , Mellibovsky Leonardo , Grinberg Daniel , Tusquets Ignasi , Diez-Perez Adolfo , Nogues Xavier

Bone density (BMD) loss is a consequence of aromatase inhibitors (AI) treatment of breast cancer. B-ABLE cohort includes 391 postmenopausal women with early breast cancer starting AI therapy. Participants experienced a 1.98% (95% CI 1.54–2.42% P<0.0001) bone loss at lumbar spine (LS) and 1.24% (95% CI 0.81–1.67% P<0.0001) bone loss at femoral neck (FN) after 1 year on AI therapy and a 3.51% (95% CI 3.00–4.03% P<0.0001) bone...

ba0006oc22 | (1) | ICCBH2017

Type I collagen C-propeptide cleavage deficiency increases bone mineralization and alters bone cell differentiation

Barnes Aileen , Perosky Joseph , Blouin Stephane , Rajpar M. Helen , Khoury Basma , Weis MaryAnn , Klaushofer Klaus , Roschger Paul , Eyre David , Fratzl-Zelman Nadja , Kozloff Kenneth , Marini Joan

High Bone Mass (HBM) osteogenesis imperfecta (OI) is caused by dominant mutations in the C-propeptide cleavage site of COL1A1 or COL1A2, characterized by bone hypermineralization. To elucidate the role of C-propeptide processing in bone mineralization and development, we generated heterozygous HBM mice with both residues (Ala-Asp) of the COL1A1 cleavage site substituted (Thr-Asn) to prevent processing by BMP1. Two, 6- and 12-month WT and HBM bones were examin...

ba0001pp232 | Cell biology: osteoclasts and bone resorption | ECTS2013

The use of photo-activatable fluorophores to study the turnover of the receptor activator of NFκB receptor in health and disease

Mellis David , Duthie Angela , Clark Susan , Crockett Julie

Familial expansile osteolysis (FEO) is characterised by focal areas of increased bone turnover driven by bone-resorbing osteoclasts. The syndrome is caused by a heterozygous tandem insertion duplication mutation within the signal peptide region of TNFRSF11a (encoding receptor activator of NFκB; RANK). Our recent research has demonstrated that heterotrimeric receptor formation may hold the key to the disease phenotype. We have shown previously that, whilst homozygous overe...

ba0004p157 | (1) | ICCBH2015

Hypoxia inducible factor-1α directly induces the expression of receptor activator of nuclear factor-κB ligand in MLO-Y4 osteocytes

Baek Kyunghwa , Park Hyun-jung , Baek Jeong-hwa

Osteocytes may function as mechanotransducers by regulating local osteoclastogenesis. Reduced availability of oxygen, i.e. hypoxia could occur during disuse, bone development and fracture. Receptor activator of nuclear factor-κB ligand (RANKL) is an osteoblast/stromal cell derived essential factor for osteoclastogenesis. Hypoxia induced osteoclastogenesis via increased RANKL expression in osteoblasts was demonstrated. Hypoxic regulation of gene expression general...